Anyone have info/ insight when Amgen will start posting jobs for this, and when they want sales force in place?
I doubt that, they are hiring regional managers and interviewing for district managers right now and a lot (if not most) are still posted on the careers site. They are listed as “respiratory biologics” positions and Amgen will definitely not be managing AZ reps. And I’m also pretty sure I read that Teze did not fare so well in AD studies but I may be wrong there... My assumption has always been that teze was going to launch along the same lines as Dupixent. Start with a small sales force covering multiple specialties, see how it goes and then expand to more targeted sleeves if the brand is successful. Only time will tell if the drug will be able to overcome the P3 flunk of decreasing OCS use. But it all starts in respiratory.
Yes indeed, whoever the original poster is (probably some stupid CI firm like Molekule) you are late to the party. And certainly not from Amgen or you would already know this. Troll go away.
Poor TZ, already a dud. Some product managers were very arrogant and cocky about this launch back in the fall, but there would be no reason to use it instead of Dupixent.... And it’s already gone.
I don’t think that’s true, the non eosinophilic asthma population is a large market that currently Dupixent can only serve if they are OCS dependent. They will likely have another trial to reassess the Effectiveness in the OCS dependent population based on the flawed trial methodology. May even go back to the other trial (navigator) and do a sub-analysis on OCS dependent patients within that trial To find other conflicting data to leave it up for debate. Then it comes down to whoever is the best rep. It certainly doesn’t help with the trial failing but it could have broader use than dupixent, especially if the safety profile is better.
Amgen's next drug will be called Beelzebub since you feel you will be working with him if you are here.
Label aside, this will be another dumpster fire collaboration. The Teze head of sales just bailed from the migraine collaboration with Novartis, you think asthma will be any different? He will hire all his Enbrel friends and both companies will be jockeying for control, sound familiar? Run for the hills on this one folks, Amg is too late to the party for asthma.
Missing on AD is telling. Not hitting on OCS is as well. Based on the MOA story, there should be fantastic efficacy. Tezepelumab was supposed to be like IL-4, IL-5, and IL-13 wrapped into one. Now it’s maybe like an IL-5?
agree. good guy. who knows who will get hired though as far as managers. it won't be a dud. Amgen has great products. you will be faced with lower salaries, poor raises and a.lot of web exes here. conference calls a lot. processes are bad, drugs here are good managers some great some bad if you need a job, come here as you will get 2 shut downs and 401 k of 10%. vacation time isn't great but 2 shut downs.
